Preventing Collateral Damage in Crohn's Disease: The Lémann Index
Gionata Fiorino1, Cristiana Bonifacio2, Laurent Peyrin-Biroulet3
1Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
Journal of Crohn'S & Colitis
|January 9, 2016
Summary
Crohn
Area of Science:
- Gastroenterology
- Inflammatory Bowel Disease Research
Background:
- Crohn's disease (CD) is a chronic condition causing progressive bowel damage in half of patients within 10 years.
- Preventing organ damage from CD complications like fistulas and strictures is a new therapeutic goal, similar to managing joint damage in rheumatoid arthritis.
Purpose of the Study:
- To introduce the Lemann Index (LI) as a tool to measure and track Crohn's disease-related bowel damage.
- To highlight the potential of the LI in evaluating therapeutic strategies aimed at preventing disease progression.
Main Methods:
- The Lemann Index (LI) was developed to quantify CD-related bowel damage.
- The LI assesses damage progression over time to evaluate the impact of treatments.
Main Results:
- Recent findings suggest that bowel damage in Crohn's disease may be reversible with anti-tumour necrosis factor (TNF) therapy.
- The Lemann Index is proposed as a key tool for CD management and future clinical trials.
Conclusions:
- The Lemann Index is a promising tool for measuring Crohn's disease bowel damage and its progression.
- Implementing the LI in clinical trials could significantly advance the evaluation of new therapeutic strategies for Crohn's disease.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
10.8K
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
10.6K
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
663
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
663
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
738
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
738
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
620
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
620
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.5K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.5K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
931
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
931